{{Drugbox
| IUPAC_name        = 1-(4-Hydroxyphenyl)-1-propanone
| image             = Paroxypropione.svg
| CAS_number        = 70-70-2
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 6271
| DrugBank          = 
| ChemSpiderID      = 6035
| chemical_formula =
| C=9 | H=10 | O=2 
| molecular_weight  = 150.175 g/mol
| SMILES = CCC(=O)c1ccc(cc1)O
| synonyms          = NSC-2834, 4'-hydroxypropiophenone, ethyl p-hydroxyphenyl ketone, p-propionylphenol, paroxypropiophenone
| StdInChI          = 1S/C9H10O2/c1-2-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3
| StdInChIKey       = RARSHUDCJQSEFJ-UHFFFAOYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Rx-only
| routes_of_administration = 
}}

'''Paroxypropione''' is a manufactured, [[nonsteroidal]] [[estrogen]] that has been used medically as an [[antigonadotropin]] in [[Spain]] and [[Italy]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA662|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=662–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA796|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=796–}}</ref><ref name="PaulsenMortimore1951">{{cite journal|last1=Paulsen|first1=C. Alvin|last2=Mortimore|first2=Glenn E.|last3=Heller|first3=Carl G.|title=THE PITUITARY ACTION AND ESTROGENIC EFFECT OF PARAHYDROXYPROPIOPHENONE|journal=The Journal of Clinical Endocrinology & Metabolism|volume=11|issue=8|year=1951|pages=892–894|issn=0021-972X|doi=10.1210/jcem-11-8-892}}</ref><ref name="Mombelli2012">{{cite journal|last1=Mombelli|first1=E.|title=Evaluation of the OECD (Q)SAR Application Toolbox for the profiling of estrogen receptor binding affinities|journal=SAR and QSAR in Environmental Research|volume=23|issue=1-2|year=2012|pages=37–57|issn=1062-936X|doi=10.1080/1062936X.2011.623325}}</ref> Paroxypropione was first synthesized in 1902.<ref name="Elks2014" /> Its antigonadotropic properties were discovered in 1951<ref name="PaulsenMortimore1951" /> and it entered clinical use shortly thereafter.<ref name="Buu-HoiXuong1953">{{cite journal|last1=Buu-Hoi|first1=Ng. Ph.|last2=Xuong|first2=Ng. D.|last3=Lavit|first3=Denise|title=Fluorine-containing analogs of 4-hydroxypropiophenone|journal=The Journal of Organic Chemistry|volume=18|issue=8|year=1953|pages=910–915|issn=0022-3263|doi=10.1021/jo50014a002}}</ref>

Paroxypropione is closely related structurally to [[4-hydroxybenzoic acid|''p''-hydroxybenzoic acid]] and [[paraben]]s such as [[methylparaben]], and also bears a close resemblance to [[diethylstilbestrol]] (which, in fact, produces paroxypropione as an [[active metabolite]])<ref name="ChambersGünzel2013">{{cite book|author1=P.L. Chambers|author2=P. Günzel|title=Mechanism of Toxic Action on Some Target Organs: Drugs and Other Substances|url=https://books.google.com/books?id=zUH1CAAAQBAJ&pg=PA276|date=12 March 2013|publisher=Springer Science & Business Media|isbn=978-3-642-67265-1|pages=276–}}</ref><ref name="GottschlichMetzler1979">{{cite journal|last1=Gottschlich|first1=Regina|last2=Metzler|first2=Manfred|title=High-pressure, reverse-phase partition chromatography separation of diethylstilbestrol metabolites and analogs|journal=Analytical Biochemistry|volume=92|issue=1|year=1979|pages=199–202|issn=0003-2697|doi=10.1016/0003-2697(79)90645-6}}</ref> and [[alkylphenol]]s like [[nonylphenol]], all of which are also estrogens.<ref name="JonesLopez2013">{{cite book|author1=Richard E. Jones|author2=Kristin H. Lopez|title=Human Reproductive Biology|url=https://books.google.com/books?id=M4kEdSnS-pkC&pg=PA46|date=28 September 2013|publisher=Academic Press|isbn=978-0-12-382185-0|pages=46–}}</ref><ref name="pmid16021681">{{cite journal | vauthors = Pugazhendhi D, Pope GS, Darbre PD | title = Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines | journal = J Appl Toxicol | volume = 25 | issue = 4 | pages = 301–9 | year = 2005 | pmid = 16021681 | doi = 10.1002/jat.1066 | url = }}</ref> The drug possesses relatively low [[affinity (pharmacology)|affinity]] for the [[estrogen receptor]]<ref name="Mombelli2012" /> and must be given at high dosages to achieve significant estrogenic and antigonadotropic action, for instance, 0.8 to 1.6 g/day.<ref name="DeVegaRuiz1955">{{cite journal | title = Protein breakdown before and after operations. Influence of growth hormone and of inhibitors of the pituitary adrenal system. | last = De Vega Ruiz | first = T | journal = Cirug., Ginecol. Urol. | year = 1955 | volume = 9 | pages = 289–326 | url = http://www.cabdirect.org/abstracts/19561404674.html}}</ref><ref name="pmid5006470">{{cite journal | vauthors = Bussolati C, de Carneri I, Castellino S, Marinoni V, Sperzani GL | title = Treatment of Experimental and Clinical Schistosomiasis with Hormonal Inhibitors of Ovulation | journal = Am. J. Trop. Med. Hyg. | volume = 16 | issue = 4 | pages = 497–9 | year = 1967 | pmid = 5006470 | doi = | url = http://www.ajtmh.org/content/16/4/497.extract}}</ref> It possesses 0.1% of the estrogenic activity of [[estrone]] and less than 0.5% of the antigonadotropic activity of estrone.<ref name="ScottKroc1952">{{cite journal|last1=Scott|first1=Charles C.|last2=Kroc|first2=Robert L.|last3=Stasilli|first3=Neil R.|title=METABOLIC AND TOXICITY STUDIES ON PARA-HYDROXYPROPIOPHENONE|journal=Endocrinology|volume=50|issue=6|year=1952|pages=607–611|issn=0013-7227|doi=10.1210/endo-50-6-607}}</ref>

Similarly to ''p''-hydroxybenzoic acid,<ref name="VafiadisBakalbassis2003">{{cite journal|last1=Vafiadis|first1=Anastasios P.|last2=Bakalbassis|first2=Evangelos G.|title=A computational study of the structure-activity relationships of some p-hydroxybenzoic acid antioxidants|journal=Journal of the American Oil Chemists' Society|volume=80|issue=12|year=2003|pages=1217–1223|issn=0003-021X|doi=10.1007/s11746-003-0845-3}}</ref> paroxypropione has been found to possess [[antioxidant]] activity.<ref name="KireseeSaghana2015">{{cite journal | title = Free Radical Scavenging Activity of 4-Hydroxypropiophenone by In Vitro Assays | last1 = Kiresee Saghana | first1 = PR | last2 = Hemalatha | first2 = S | journal = World Journal of Pharmacy and Pharmaceutical Sciences | volume = 4 | issue = 12 | pages = 935–950 | issn = 2278-4357 | url = http://www.wjpps.com/download/article/1448873223.pdf}}</ref>

==Synthesis==
In the best case, a ~96% yield was reported from the reaction between phenol and [[propionyl chloride]].<ref>Murashige, Ryo; Hayashi, Yuka; Ohmori, Syo; Torii, Ayuko; Aizu, Yoko; Muto, Yasuyuki; Murai, Yuta; Oda, Yuji; Hashimoto, Makoto Tetrahedron, 2011, vol. 67, # 3 p. 641 - 649.</ref> The mechanism is likely to involve initial ester formation, followed by a [[Fries rearrangement]].

==Names==
Brand names Frenantol, Frenormon, Hypophenon, Paroxon, Possipione, Profenone, numerous others; former developmental code name NSC-2834), also known as paroxypropiophenone (P.O.P.) or 4'-hydroxypropiophenone.

==[[Derivative (chemistry)|Derivatives]]==
Paroxypropione is a [[precursor (chemistry)|precursor]] in the [[chemical synthesis]] of:
# Nonsteroidal [[stilbestrol]] estrogens including: [[diethylstilbestrol]], [[dienestrol]] and [[Hexestrol]] 
#[[Fenalcomine]]
#[[Buphenine]] which itself is a precursor to [[Bufeniode]].
#[[Isoxsuprine]]
#[[Ractopamine]]
#[[Fenprodil]] & [[Traxoprodil]]
#A patent for para-hydroxy-[[phenylpropanolamine]] was also disclosed.<ref>Walter H Hartung, {{US patent|1995709}} (1935 to Sharp & Dohme Inc).</ref>
#DE547174 describes the synthesis of [[Oxilofrine]].

==See also==
<!-- new links in alphabetical order please -->
{{colbegin|3}}
* [[Acefluranol]]
* [[Bifluranol]]
* [[Carbestrol]]
* [[Doisynolic acid]]
* [[Fenestrel]]
* [[Metallibure]]
* [[Quadrosilan]]
* [[Stilbestrol]]
* [[Triphenylethylene]]
{{colend}}

==References==
{{Reflist|2}}

==Further reading==
* {{cite journal | vauthors = GUSTAVO RP | title = [Anti-gonadotropic action of possipione] | language = Italian | journal = Quad Clin Ostet Ginecol | volume = 13 | issue = 7 | pages = 307–15 | year = 1958 | pmid = 13579130 | doi = | url = }}

{{Estrogens}}
{{Antigonadotropins}}
{{Estrogenics}}

[[Category:Antigonadotropins]]
[[Category:Antioxidants]]
[[Category:Aromatic ketones]]
[[Category:Hormonal agents]]
[[Category:Synthetic estrogens]]